Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schulze-Bahr, E.
Right arrow Articles by Breithardt, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schulze-Bahr, E.
Right arrow Articles by Breithardt, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Genetic aspects in acquired long QT syndrome — a piece in the puzzle

E. Schulze-Bahr1, W. Haverkamp, L. Eckardt, P. Kirchhof, H. Wedekind and G. Breithardt

Department of Cardiology and Angiology, Hospital of the University of Munster, and Institute for Arteriosclerosis Research at the University of Munster, Germany

1 Correspondence: Eric Schulze-Bahr, MD, Department of Cardiology and Angiology, Hospital of the University of Münster, D-48129 Münster, Germany.

Abstract

Torsade de pointes (TdP) is a serious complication which is induced by a large variety of cardiovascular and non-cardiovascular drugs. Many clinical conditions and risk factors for the occurrence of TdP during administration of drugs with a proarrhythmic potential have been identified. All such drugs have in common that they reversibly alter myocardial repolarization due to the prolongation of the action potential (acquired QT interval prolongation) which is per se not arrhythmogenic. TdP is initiated (acquired long QT (LQT) syndrome) only when a threshold level is reached leading to early after-depolarizations (EADs) and triggered beats together with a marked dispersion in recovery of excitability. The underlying mechanisms of TdP are not yet satisfactorily elucidated but, in general, alterations in cardiac ion currents which tune the normal action potential play a major role in arrhythmogenesis.

Following recent advances in molecular biology and genetics, it has become clear that in some clinical instances (e.g. congestive heart failure or cardiac hypertrophy) ion channel genes become less expressed (down-regulated) and the consequent reduced ion currents (e.g. IKr) are likely to cause prolonged myocardial repolarization. In this setting, the use of drugs with action potential-prolonging properties could possibly be harmful and could not be compensated by the normal cardiac ‘repolarization reserve’. In congenital LQT syndrome some of the same ion channel components were found to be genetically altered, suggesting that either quantitative or qualitative changes of ion currents may be involved in ventricular arrhythmogenesis through similar mechanisms (‘final common pathway’). A variable clinical expressivity and, especially, an incomplete penetrance has been found in patients carrying the same LQT genotype, even when near-relatives, which raises the question on the frequency and importance of ‘silent’ (i.e. minor functional) ion channel gene mutations that may become functionally significant in presence of action potential prolonging drugs and other coexisting factors. The observation of adverse drug reactions in apparently healthy (‘normal heart’) individuals is suggestive of a genetic susceptibility for ‘acquired’ arrhythmias. This report reviews and summarizes the recent knowledge on unapparent ion channel gene mutations and preliminary concepts about ‘acquired’ arrhythmias.

Key Words: Long QT syndrome • torsade de pointes • KCNQ1 • HERG • ventricular repolarization • IKr • IKs•

References

  1. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart. 2000;21:1216–1231
  2. Haverkamp W, Mönnig G, Eckardt L, et al. Mechanisms and clinical aspects of ventricular arrhythmias associated with QT prolongation: Torsade de pointes. Oto A, Breithardt G. Myocardial repolarization-from gene to bedside. New York: Armonk, Futura Publishing Company; 2001. (in press)
  3. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625–1633[CrossRef][Web of Science][Medline]
  4. Näbauer M, Kääb S. Potassium channel down-regulation in heart failure. Cardiovasc Res. 1998;37:324–334[CrossRef][Web of Science][Medline]
  5. Tomaselli GF, Marban E. Electrophysiological remodelling in hypertrophy and heart failure. Cardiovasc Res. 1999;52:270–283
  6. Eckardt L, Haverkamp W, Johna R, et al. Arrhythmias in heart failure: current concepts of mechanisms and therapy. J Cardiovasc Electrophysiol. 2000;11:106–117[Web of Science][Medline]
  7. Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medical Products. Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997.
  8. Breithardt G, Borggrefe M, Schulze-Bahr E, Haverkamp W. How to avoid drug-induced torsade de pointes. Oto A, Breithardt G. Myocardial repolarization — from gene to bedside. New York: Armonk, Futura Publishing Company; 2001. (in press)
  9. Cavero I, Mestre M, Guillont J-M, Crumb W. Drugs that prolong QT intervals as an unwanted effect; assessing their likelihood of inducing hazardous cardiac dysrrhythmias. Exp Opin Pharmacother. 2000;1:947–973[CrossRef][Medline]
  10. Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029–1034[CrossRef][Medline]
  11. Crumb W, Cavero I. QT interval prolongation by noncardiovascular drugs: issues and solutions for novel drug development. PSTT. 1999;2:270–278
  12. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;225:1358–1361
  13. Schulze-Bahr E, Haverkamp W, Borggrefe M, et al. Molecular genetics of arrhythmias—a new paradigm. Z Kardiol. 2000;89:IV12–IV22 (Suppl)
  14. Schulze-Bahr E, Haverkamp W, Denjoy I, Guicheney P, Breithardt G. Genetic aspects in acquired long-QT syndrome-Is there a genetic basis? Oto A, Breithardt G. Myocardial repolarization-from gene to bedside. New York: Futura Publishing Company; 2001. (in press)
  15. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997;96:2778–2781[Abstract/Free Full Text]
  16. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovase Dis. 1988;31:115–172
  17. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088–1093[CrossRef][Web of Science][Medline]
  18. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984;107:425–430[CrossRef][Web of Science][Medline]
  19. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7:547–557[Web of Science][Medline]
  20. Lehmann MIL, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex differences in risk of torsade de pointes with (d,l) sotalol. Circulation. 1996;94:2535–2541[Abstract/Free Full Text]
  21. Haverkamp W, Mönnig G, Eckardt L, et al. Acquired abnormal QT prolongation and torsade de pointes -clinical significance of genetic information from congenital long QT syndrome. Zehender M, Breithardt G, Just H. From molecule to men-Molecular basis of congenital cardiovascular disorders. Darmstadt: Steinkopf-Verlag; 2000. p. 99–112
  22. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. J Am Med Assoc. 1993;270:2590–2597[Abstract/Free Full Text]
  23. Kurita T, Ohe T, Shimizu W, Hotta D, Shimomura K. Early afterdepolarization in a patient with complete atrioventricular-block and torsades-de-pointes. Pac Clin Electrophysiol. 1993;16:33–38
  24. Wedekind H, Schulze-Bahr E, Haverkamp W, et al. Low penetrance of a missense mutation in chromosome 11-specific long-QT syndrome (LQTS1). Med Genet. 1997;9:43 (Suppl)
  25. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome [see comments]. N Engl J Med. 1992;327:846–852[Abstract]
  26. Neyroud N, Denjoy I, Donger C, et al. Heterozygous mutation in the pore of potassium channel gene KvLQT1 causes an apparently normal phenotype in long QT syndrome. Eur J Hum Genet. 1992;6:129–133
  27. Neyroud N, Tesson F, Denjoy I, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15:186–189[CrossRef][Web of Science][Medline]
  28. Splawski I, Timothy KW, Vincent GM, Atkinson DL, Keating MT. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med. 1997;336:1562–1567[Free Full Text]
  29. Schulze-Bahr E, Wang Q, Wedekind H, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet. 1997;17:267–268[CrossRef][Web of Science][Medline]
  30. Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M, Jervell Lange-Nielsen syndrome: a Norwegian perspective. Am J Med Genet. 1999;89:137–146[CrossRef][Web of Science][Medline]
  31. Priori SG, Schwartz PL, Napolitano C, et al. A recessive variant of the Romano-Ward long-QT syndrome? Circulation. 1998;97:2420–2425[Abstract/Free Full Text]
  32. Priori SG, Napolitano C, Schwartz PL. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999;99:529–533[Abstract/Free Full Text]
  33. Eur Heart J. 1998;19:1178–1196[Free Full Text]
  34. The Working Group of the European Society of Cardiology. The Sicilian Gambit. Circulation. 1991;84:1831–1851[Abstract/Free Full Text]
  35. Towbin JA. Cardiac arrhythmias: the genetic connection. J Cardiovasc Electrophysiol. 2000;11:601–602[Web of Science][Medline]
  36. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299–307[CrossRef][Web of Science][Medline]
  37. Mitcheson IS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 8th edn. 2000. p. 12329–12333
  38. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of high-affinity dofetilide binding to HERGI expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol. 2000;57:367–374[Abstract/Free Full Text]
  39. Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM. Molecular determinants of dofetilide block of HERG K+ channels. Circ Res. 1998;82:386–395[Abstract/Free Full Text]
  40. Abbott GW, Sesti F, Splawski I, et al. MiRPI forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97:175–187[CrossRef][Web of Science][Medline]
  41. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 1996;385:77–80[CrossRef][Web of Science][Medline]
  42. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA. 2000;97:10613–10618[Abstract/Free Full Text]
  43. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation. 2000;101:1749–1753[Free Full Text]
  44. Schulze-Bahr E, Haverkamp W, Hördt M, Wedekind H, Borggrefe M, Funke H. Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long-QT syndrome? Circulation. 1997;96:I–210 (Suppl)
  45. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 2000;11:691–696[Web of Science][Medline]
  46. Berthet M, Denjoy I, Donger C, et al. C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. Circulation. 1999;99:1464–1470[Abstract/Free Full Text]
  47. Kubota T, Shimizu W, Kamakura S, Horie M. Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4–S5 linker of KCNQ1. J Cardiovasc Electrophysiol. 2000;11:1048–1054[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schulze-Bahr, E.
Right arrow Articles by Breithardt, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schulze-Bahr, E.
Right arrow Articles by Breithardt, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?